In a phase 3 trial, the agent reduces seizure frequency by up to 53% in treatment-resistant focal epilepsy, with rapid onset ...

The study sought to evaluate the efficacy, safety, and tolerability of azetukalner, administered as an oral, adjunctive, once ...

Low dose resulted in 89% median disabling seizure reduction in participants with MTS during the 7-12-month primary efficacy ...

Poststroke epilepsy is linked to a significantly higher risk for dementia, suggesting a need for increased surveillance and ...

With the 25 mg dose, reductions in weekly seizures were seen in the first week of treatment, she noted. At 12 weeks, Patient ...

Add Yahoo as a preferred source to see more of our stories on Google. More than 3.4 million people in the United States have epilepsy, so it is a relatively common diagnosis. In fact, it is the fourth ...